# A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)

> **NCT00978250** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 95 (actual)

## Conditions studied

- Head and Neck Neoplasms
- Lung Neoplasms
- Urinary Bladder Neoplasms
- Breast Neoplasms

## Interventions

- **DRUG:** 5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)

## Key facts

- **NCT ID:** NCT00978250
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08-20
- **Primary completion:** 2019-04-11
- **Final completion:** 2019-04-11
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2019-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00978250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00978250, "A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00978250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*